Eyeworld Daily News

13 EW SHOW DAILY ASCRS•ASOA Symposium & Congress, New Orleans 2016 Mr. Wilkinson noted that lead- ership is not linked to authority, and that some managers never learn to be leaders. "If the message doesn't inspire, there's no call to action; if I'm not engaged, if there's no content or value or worth, if I don't feel something inside me, or respect, or accountability, or a reason to follow you, then the message is seldom retained," Mr. Wilkinson said. "It's always been the messenger." For instance, when he asks managers to show their to-do list for Monday, rarely do they include "to inspire, lead, or motivate the team." "And yet, aren't we evaluated on the acts of the people we lead?" Mr. Wilkinson said. Hiring for success The success of leaders also traces back to the people they hire. Specif- ically, many of his clients are hiring for attitude and training for success. "You can alter behavior; you can't change attitude," Mr. Wilkinson said. Mr. Wilkinson said that he would prefer a short-staffed practice with inclusive, team-mind- ed people, who respect their patents and co-workers, over a fully staffed office where people are working to undermine each other. "If you can't change people, you need to change people," Mr. Wilkinson said. But he also urged the audience to give their subordinates a chance to change through honest feedback and evaluations. Customer efforts Effort to inspire needs to extend to their practice's customers. "A satisfied customer or client may leave you; a value customer or client brags about you and brings other people to you," Mr. Wilkinson said. Leaders can help their practices find that success by first creating a positive culture and then catch- ing and connecting that culture. Creating the culture means instilling an owner mindset in all employees, so they accept any initiative of the business as their own. And then leaders need to coach the culture. "You have to move it along and coach others," Mr. Wilkinson said. EW INDICATIONS AND USAGE PROLENSA ® (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-infl ammatory drug (NSAID) indicated for the treatment of postoperative infl ammation and reduction of ocular pain in patients who have undergone cataract surgery. IMPORTANT SAFETY INFORMATION ABOUT PROLENSA ® • PROLENSA ® contains sodium sulfi te, a sulfi te that may cause allergic type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfi te sensitivity in the general population is unknown and probably low. Sulfi te sensitivity is seen more frequently in asthmatic than in non-asthmatic people. • All topical nonsteroidal anti-infl ammatory drugs (NSAIDs), including bromfenac, may slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems. • There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs, including bromfenac. Use with caution in patients who have previously exhibited sensitivities to these drugs. • There have been reports that ocularly applied NSAIDs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. Use with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time. • Use of topical NSAIDs may result in keratitis. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs, including bromfenac, and should be closely monitored for corneal health. Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients. Post-marketing experience with topical NSAIDs suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events. • PROLENSA ® should not be instilled while wearing contact lenses. The preservative in PROLENSA ® , benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA ® . • The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber infl ammation, foreign body sensation, eye pain, photophobia, and blurred vision. Please see brief summary of full Prescribing Information for PROLENSA ® on adjacent page. References: 1. PROLENSA Prescribing Information, April 2013. 2. Data on fi le, Bausch & Lomb Incorporated. 3. Baklayan GA, Patterson HM, Song CK, Gow JA, McNamara TR. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. PROLENSA is a registered trademark of Bausch & Lomb Incorporated or its affi liates. © Bausch & Lomb Incorporated. All rights reserved. Printed in USA. PRA.0188.USA.15 The PROLENSA ® Effect POWERED FOR PENETRATION Advanced Formulation to Facilitate Corneal Penetration 1-3 pH e ffect Hal og en a ti on e ffect PROLENSA ® delivers potency and corneal penetration with QD dosing at a low concentration 1-3

• Cover